Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Protalix Biotherapeutics Inc PLX

Healthcare Biotechnology
Protalix BioTherapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. In addition, the Company is developing PEGylated uricase, or PRX-115, for the treatment of severe gout, Long Acting (LA) DNase I, or PRX-119, for the... see more

Recent & Breaking News (NYSEAM:PLX)

Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Submission of Biologics License Application to U.S. Food and Drug Administration for Pegunigalsidase Alfa for the Treatment of Fabry Disease

PR Newswire May 28, 2020

Protalix BioTherapeutics to Hold First Quarter 2020 Financial Results and Business Update Conference Call on June 1, 2020

PR Newswire May 22, 2020

Protalix BioTherapeutics Announces Positive Topline Results from the BRIDGE Phase III Open-Label, Switch-Over Clinical Trial Evaluating Pegunigalsidase Alfa for the Treatment of Fabry Disease

PR Newswire May 11, 2020

Protalix BioTherapeutics Announces Closing of $43.7 Million Private Placement

PR Newswire March 18, 2020

Protalix Biotherapeutics Announces Feasibility Study with Kirin Holdings on the Production of a Novel Complex Protein

PR Newswire March 16, 2020

Protalix BioTherapeutics Reports Fourth Quarter and Full Year 2019 Financial and Business Results

PR Newswire March 12, 2020

Protalix BioTherapeutics Announces $43.7 Million in Financing to Further Advance its Programs in Fabry Disease

PR Newswire March 12, 2020

Protalix BioTherapeutics to Hold Fourth Quarter and Full-Year 2019 Financial and Business Results Conference Call on March 12, 2020

PR Newswire March 5, 2020

Protalix BioTherapeutics Presents Key Clinical Data of Pegunigalsidase Alfa for the Treatment of Fabry Disease at the 16th Annual WORLDSymposium(TM) 2020

PR Newswire February 10, 2020

Protalix BioTherapeutics and Chiesi Farmaceutici Announce Receipt of "Agreement Letter" for Initial Pediatric Study Plan for PRX-102 for the Treatment of Fabry Disease

PR Newswire February 6, 2020

Protalix BioTherapeutics to Participate in the 2020 BIO CEO & Investor Conference and the Noble Capital Markets' 16th Annual Small & Microcap Investor Conference

PR Newswire February 4, 2020

Protalix BioTherapeutics to Participate in the 16th Annual WORLDSymposium(TM) 2020

PR Newswire January 30, 2020

Protalix BioTherapeutics Adds Two Accomplished Biopharmaceutical Executives to its Board of Directors

PR Newswire December 19, 2019

Protalix BioTherapeutics Announces 1-for-10 Reverse Stock Split

PR Newswire December 9, 2019

Protalix BioTherapeutics Hosting Key Opinion Leader Meeting on PRX?102 Drug Candidate for the Treatment of Fabry Disease

PR Newswire November 27, 2019

Protalix BioTherapeutics and Chiesi Farmaceutici Announce Successful pre-BLA Meeting with FDA for Accelerated Approval of pegunigalsidase alfa for the Treatment of Fabry Disease in the United States

PR Newswire November 18, 2019

Protalix BioTherapeutics Reports Third Quarter 2019 Results and Provides Corporate Update

PR Newswire November 7, 2019

Protalix BioTherapeutics to Release Third Quarter 2019 Financial Results and Business Update on November 7, 2019

PR Newswire October 29, 2019

Protalix BioTherapeutics Announces Positive 12-Month Interim Data From the BRIDGE Phase III Open Label Switch-over Study of Pegunigalsidase Alfa for the Treatment of Fabry Disease

PR Newswire October 17, 2019

Protalix BioTherapeutics and Chiesi Group Complete Enrollment in the Third Phase III Clinical Trial of pegunigalsidase alfa (PRX?102) for the Treatment of Fabry Disease

PR Newswire September 24, 2019